Format
Sort by
Items per page

Send to

Choose Destination

Best matches for ACYCLOVIR/PD:

Search results

Items: 1 to 20 of 6397

1.

Intra-cameral level of ganciclovir gel, 0.15% following topical application for cytomegalovirus anterior segment infection: A pilot study.

Waduthantri S, Zhou L, Chee SP.

PLoS One. 2018 Jan 29;13(1):e0191850. doi: 10.1371/journal.pone.0191850. eCollection 2018.

2.

[Evaluation of the Safety of 2.0% Ganciclovir Eye Drops for Hospital Preparation].

Nakagawa H, Matsumaru Y, Nose S, Sasaki H, Kitahara T.

Yakugaku Zasshi. 2018;138(1):107-110. doi: 10.1248/yakushi.17-00015. Japanese.

3.

Development of Acyclovir-Loaded Albumin Nanoparticles and Improvement of Acyclovir Permeation Across Human Corneal Epithelial T Cells.

Suwannoi P, Chomnawang M, Sarisuta N, Reichl S, Müller-Goymann CC.

J Ocul Pharmacol Ther. 2017 Dec;33(10):743-752. doi: 10.1089/jop.2017.0057. Epub 2017 Nov 7.

PMID:
29111864
4.

Houttuynoid M, an Anti-HSV Active Houttuynoid from Houttuynia cordata Featuring a Bis-houttuynin Chain Tethered to a Flavonoid Core.

Li JJ, Chen GD, Fan HX, Hu D, Zhou ZQ, Lan KH, Zhang HP, Maeda H, Yao XS, Gao H.

J Nat Prod. 2017 Nov 22;80(11):3010-3013. doi: 10.1021/acs.jnatprod.7b00620. Epub 2017 Nov 3.

PMID:
29099182
5.

Application of next-generation sequencing to detect acyclovir-resistant herpes simplex virus type 1 variants at low frequency in thymidine kinase gene of the isolates recovered from patients with hematopoietic stem cell transplantation.

Fujii H, Kakiuchi S, Tsuji M, Nishimura H, Yoshikawa T, Yamada S, Omura N, Inagaki T, Shibamura M, Harada S, Taniguchi S, Saijo M.

J Virol Methods. 2018 Jan;251:123-128. doi: 10.1016/j.jviromet.2017.10.019. Epub 2017 Oct 23.

PMID:
29074089
6.

Topical use of 5% acyclovir cream for the treatment of occult and verrucous equine sarcoids: a double-blinded placebo-controlled study.

Haspeslagh M, Jordana Garcia M, Vlaminck LEM, Martens AM.

BMC Vet Res. 2017 Oct 6;13(1):296. doi: 10.1186/s12917-017-1215-0.

7.

Antibody-based immunotherapy of aciclovir resistant ocular herpes simplex virus infections.

Bauer D, Keller J, Alt M, Schubert A, Aufderhorst UW, Palapys V, Kasper M, Heilingloh CS, Dittmer U, Laffer B, Eis-Hübinger AM, Verjans GM, Heiligenhaus A, Roggendorf M, Krawczyk A.

Virology. 2017 Dec;512:194-200. doi: 10.1016/j.virol.2017.09.021. Epub 2017 Oct 3.

8.

Inhibition of Herpes Simplex Viruses by Cationic Dextran Derivatives.

Pachota M, Klysik K, Synowiec A, Ciejka J, Szczubiałka K, Pyrć K, Nowakowska M.

J Med Chem. 2017 Oct 26;60(20):8620-8630. doi: 10.1021/acs.jmedchem.7b01189. Epub 2017 Oct 6.

PMID:
28956914
9.

Discovery of potent antiviral (HSV-1) quinazolinones and initial structure-activity relationship studies.

Brown CE, Kong T, McNulty J, D'Aiuto L, Williamson K, McClain L, Piazza P, Nimgaonkar VL.

Bioorg Med Chem Lett. 2017 Oct 15;27(20):4601-4605. doi: 10.1016/j.bmcl.2017.09.026. Epub 2017 Sep 14.

PMID:
28943043
10.

High-Dose Acyclovir for Cytomegalovirus Prophylaxis in Seropositive Abdominal Transplant Recipients.

Jorgenson MR, Descourouez JL, Leverson GE, McCreary EK, Lucey MR, Smith JA, Redfield RR.

Ann Pharmacother. 2018 Jan;52(1):5-10. doi: 10.1177/1060028017728296. Epub 2017 Aug 26.

PMID:
28844151
11.

Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report.

Echenique IA, Beltran D, Ramirez-Ruiz L, Najafian N, Agrawal N.

Transplant Proc. 2017 Sep;49(7):1560-1564. doi: 10.1016/j.transproceed.2017.02.046.

PMID:
28838440
12.

Valganciclovir for the Suppression of Epstein-Barr Virus Replication.

Yager JE, Magaret AS, Kuntz SR, Selke S, Huang ML, Corey L, Casper C, Wald A.

J Infect Dis. 2017 Jul 15;216(2):198-202. doi: 10.1093/infdis/jix263.

PMID:
28838145
13.

Self-Retained Amniotic Membrane Combined With Antiviral Therapy for Herpetic Epithelial Keratitis.

Cheng AMS, Tseng SCG.

Cornea. 2017 Nov;36(11):1383-1386. doi: 10.1097/ICO.0000000000001316.

PMID:
28834819
14.

Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.

Derudas M, Vanpouille C, Carta D, Zicari S, Andrei G, Snoeck R, Brancale A, Margolis L, Balzarini J, McGuigan C.

J Med Chem. 2017 Sep 28;60(18):7876-7896. doi: 10.1021/acs.jmedchem.7b01009. Epub 2017 Sep 19.

15.

Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial.

Limaye AP, Stapleton RD, Peng L, Gunn SR, Kimball LE, Hyzy R, Exline MC, Files DC, Morris PE, Frankel SK, Mikkelsen ME, Hite D, Enfield KB, Steingrub J, O'Brien J, Parsons PE, Cuschieri J, Wunderink RG, Hotchkin DL, Chen YQ, Rubenfeld GD, Boeckh M.

JAMA. 2017 Aug 22;318(8):731-740. doi: 10.1001/jama.2017.10569.

16.

In vivo and in vitro palatability testing of a new paediatric formulation of valaciclovir.

Bastiaans DET, Immohr LI, Zeinstra GG, Strik-Albers R, Pein-Hackelbusch M, van der Flier M, de Haan AFJ, Boelens JJ, Lankester AC, Burger DM, Warris A.

Br J Clin Pharmacol. 2017 Dec;83(12):2789-2797. doi: 10.1111/bcp.13396. Epub 2017 Sep 20.

17.

Therapeutic strategies for locally recurrent and metastatic de-differentiated liposarcoma with herpes simplex virus-thymidine kinase-expressing mesenchymal stromal cells.

Lee H, Jo EB, Kim SJ, Yang HM, Kim YM, Sung YC, Park JB, Hong D, Park H, Choi YL, Kim SJ.

Cytotherapy. 2017 Sep;19(9):1035-1047. doi: 10.1016/j.jcyt.2017.05.008. Epub 2017 Jul 29.

PMID:
28760351
18.

Effectiveness of Valganciclovir 900mg Versus 450mg for Cytomegalovirus Prophylaxis in Renal Transplantation: A Systematic Review and Meta-Analysis.

Xin W, Hui Y, Xiaodong Z, Xiangli C, Shihui W, Lihong L.

J Pharm Pharm Sci. 2017;20(0):168-183. doi: 10.18433/J3805B. Review.

19.

Enteric Glia Regulate Gastrointestinal Motility but Are Not Required for Maintenance of the Epithelium in Mice.

Rao M, Rastelli D, Dong L, Chiu S, Setlik W, Gershon MD, Corfas G.

Gastroenterology. 2017 Oct;153(4):1068-1081.e7. doi: 10.1053/j.gastro.2017.07.002. Epub 2017 Jul 13.

PMID:
28711628
20.

Functionalized PLA-PEG nanoparticles targeting intestinal transporter PepT1 for oral delivery of acyclovir.

Gourdon B, Chemin C, Moreau A, Arnauld T, Baumy P, Cisternino S, Péan JM, Declèves X.

Int J Pharm. 2017 Aug 30;529(1-2):357-370. doi: 10.1016/j.ijpharm.2017.07.024. Epub 2017 Jul 10.

PMID:
28705621

Supplemental Content

Loading ...
Support Center